EU approves AstraZeneca's Imfinzi─in combo with chemotherapy to treat patients with resectable non─small cell lung ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no epidermal growth factor …